Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 0.45 |
| ▸ | WDR5 | P61964 | 5/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | BCR | P11274 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.37 |
| ▸ | CASR | P41180 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2478564 | 0.91 | MCHR1 (0.43) | EGFRKDM1AMCHR1ALDH1A1MAPT | |
| SCHEMBL2477767 | 0.89 | ALDH1A1 (0.43) | EGFRWDR5KDM1AMCHR1ALDH1A1 | |
| SCHEMBL2480501 | 0.89 | MAPT (0.46) | EGFRWDR5KDM1AMCHR1ALDH1A1 | |
| SCHEMBL2480569 | 0.89 | EGFR (0.47) | EGFRWDR5ABL1BCRMCHR1 | |
| SCHEMBL3830942 | 0.87 | KDM1A (0.45) | KDM1AMCHR1MAPTLMNABRAF | |
| SCHEMBL3832833 | 0.87 | HDAC1 (0.46) | ALDH1A1MAPTGAASMN1; SMN2LMNA | |
| SCHEMBL3835064 | 0.86 | KDM1A (0.45) | EGFRKDM1AMCHR1ALDH1A1MAPT | |
| SCHEMBL2476793 | 0.84 | ALDH1A1 (0.49) | KDM1AALDH1A1MAPTGAAMAPK1 | |
| SCHEMBL3832544 | 0.83 | TNF (0.46) | KDM1AALDH1A1MAPTGAA | |
| SCHEMBL3835504 | 0.83 | TP53 (0.45) | ALDH1A1MAPTGAASMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076332-B2 | N- (2-aminophenyl) benzamide derivative having urea structure | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-12-13 | — | — | US | disclosed |
| EP-2107052-B1 | NOVEL N-(2-AMINOPHENYL)BENZAMIDE DERIVATIVE HAVING AN UREA STRUCTURE | SANTEN PHARMACEUTICAL CO LTD (JP) | 2011-10-12 | — | — | EP | disclosed |
| US-20090306077-A1 | NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-12-10 | — | — | US | disclosed |
| EP-2107052-A1 | NOVEL N-(2-AMINOPHENYL)BENZAMIDE DERIVATIVE HAVING AN UREA STRUCTURE | Santen Pharmaceutical Co., Ltd (JP) | 2009-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306077-A1 | NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE | UACA, SLC14A1, ARG2 | EGFR 2604/4885WDR5 3290/4885ABL1 3053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.